231 related articles for article (PubMed ID: 32665698)
1. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
[TBL] [Abstract][Full Text] [Related]
2. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
[TBL] [Abstract][Full Text] [Related]
3. Statins inhibit blastocyst formation by preventing geranylgeranylation.
Alarcon VB; Marikawa Y
Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
[TBL] [Abstract][Full Text] [Related]
4. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
5. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
Du T; Song Y; Ray A; Chauhan D; Anderson KC
Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
[TBL] [Abstract][Full Text] [Related]
8. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
10. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins.
Yu R; Longo J; van Leeuwen JE; Mullen PJ; Ba-Alawi W; Haibe-Kains B; Penn LZ
Cancer Res; 2018 Mar; 78(5):1347-1357. PubMed ID: 29229608
[TBL] [Abstract][Full Text] [Related]
11. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.
Xia Z; Tan MM; Wong WW; Dimitroulakos J; Minden MD; Penn LZ
Leukemia; 2001 Sep; 15(9):1398-407. PubMed ID: 11516100
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis.
Nagashima T; Okazaki H; Yudoh K; Matsuno H; Minota S
Arthritis Rheum; 2006 Feb; 54(2):579-86. PubMed ID: 16447234
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
[TBL] [Abstract][Full Text] [Related]
14. Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells.
Tu C; Du Z; Zhang H; Feng Y; Qi Y; Zheng Y; Liu J; Wang J
Theranostics; 2021; 11(5):2364-2380. PubMed ID: 33500730
[TBL] [Abstract][Full Text] [Related]
15. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.
Clendening JW; Pandyra A; Li Z; Boutros PC; Martirosyan A; Lehner R; Jurisica I; Trudel S; Penn LZ
Blood; 2010 Jun; 115(23):4787-97. PubMed ID: 20360469
[TBL] [Abstract][Full Text] [Related]
16. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.
Tanaka T; Tatsuno I; Uchida D; Moroo I; Morio H; Nakamura S; Noguchi Y; Yasuda T; Kitagawa M; Saito Y; Hirai A
J Neurosci; 2000 Apr; 20(8):2852-9. PubMed ID: 10751437
[TBL] [Abstract][Full Text] [Related]
17. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
19. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
20. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
